Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Filings indexed 310 across all filing types
Latest filing 2024-08-28 Director's Dealing
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
4
Director's Dealing
2024-08-28 English
4
Director's Dealing
2024-08-28 English
Regulatory Filings 2024
Regulatory Filings
2024-08-23 English
10-Q
Interim / Quarterly Report Q2 2024
2024-08-12 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 12, 2024, reporting the issuance of a press release announcing financial results for the second quarter ended June 30, 2024. The text explicitly states that the press release is furnished as an exhibit and that the Form 8-K itself is a current report, not the full financial report. The document length is 3715 characters, which is relatively short and consistent with a regulatory announcement rather than a full financial report. The content corresponds to an initial announcement of quarterly financial results, which aligns with the definition of an Earnings Release (ER). Therefore, the appropriate classification is Earnings Release (ER).
2024-08-12 English
4
Director's Dealing
2024-06-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.